Abstracts Archive - Page 1110 of 2607 - ACR Meeting Abstracts

Abstract Number: 2549 • 2019 ACR/ARP Annual Meeting
Population Pharmacokinetics of Atacicept in Systemic Lupus Erythematosus (SLE) – an Analysis of Three Clinical Trials
Maria Pitsui ¹, Orestis Papasouliotis², Colm Farrell ¹, Pascal Girard ², Oezkan Yalkinoglu ³ and Cristina Vazquez-Mateo ⁴, ¹ICON Plc, Dublin, Ireland, ²Merck Institute for Pharmacometrics, Lausanne, Switzerland, ³Merck KGaA, Darmstadt, Germany, ⁴EMD Serono Research and Development Institute, Inc., Billerica, MA
Background/Purpose: Atacicept targets the B-cell stimulating factors BLyS and APRIL and has been shown to reduce SLE disease activity. The aim of the analysis was…
Abstract Number: 2550 • 2019 ACR/ARP Annual Meeting
Impact of Pathogenic and Protective Environmental Exposures on Autoimmune Disease—The Microbiome Effects on Lupus (MEL) Study
Hayley Walter¹, Trevor Faith ², Alexander Alekseyenko ³, Ali Bakhtiari ³, Paula Ramos ² and Diane Kamen ⁴, ¹Division of Rheumatology/Medical University South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³Medical University South Carolina, Charleston, SC, ⁴Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic and often severe multi-organ autoimmune disease characterized by the production of autoantibodies and heterogeneous clinical manifestations. African…
Abstract Number: 2551 • 2019 ACR/ARP Annual Meeting
Validity and Reliability of Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Tests (CAT) in a Canadian Cohort of Patients with Systemic Lupus Erythematosus
Mitra Moazzami¹, Lisa Engel ², Nicole Anderson ³, Jiandong Su ³, Dennisse Bonilla ³, Pooneh Akhavan ⁴, Patricia Katz ⁵, Dorcas Beaton ⁶ and Zahi Touma ⁷, ¹George Washington University, Washington, DC, ²University of Manitoba, Winnipeg, MB, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, Canada, ⁵University of California, San Francisco, san francisco, CA, ⁶St. Michael's Hospital, Toronto, ON, Canada, ⁷University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Patient-reported outcome measures are invaluable tools in clinical practice and are central in providing patient-centered care. There has been minimal research on the use…
Abstract Number: 2552 • 2019 ACR/ARP Annual Meeting
Design and Development of an Online Intervention for Lupus Self-Management Based on the Transtheoretical Model of Change
Sarah Gilman ¹, Deborah Levesque ², Carol Cummins ³, Daniel Wallace ⁴, Victoria Werth ⁵ and Patricia Davidson⁶, ¹Wayfinder Health Strategies, Washington, DC, ²Pro-Change Behavior Systems, Providence, RI, ³Pro-Change Behavior Systems, Inc.,, Providence, ⁴Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁵Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁶Lupus Foundation of America, Washington, DC
Background/Purpose: The Lupus Foundation of America is in Year 4 of a 6-year cooperative agreement with the Centers for Disease Control and Prevention to develop…
Abstract Number: 2553 • 2019 ACR/ARP Annual Meeting
Prescription Opioid Use and Osteoporotic Fractures in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology & Surveillance (MILES) Cohort
Emily Somers¹, Sioban Harlow ¹, Nina Zhou ¹, Lu Wang ¹, Kamil Barbour ², Charles Helmick ³, Caroline Gordon ⁴, Deeba Minhas ¹, Beth Wallace ¹, Afton Hassett ¹, Suzanna Zick ¹, W. Joseph McCune ⁵ and Wendy Marder ¹, ¹University of Michigan, Ann Arbor, ²Centers for Disease Control and Prevention, Atlanta, ³Centers for Disease Control and Prevention, Division of Population Health, Atlanta, GA, ⁴University of Birmingham, Birmingham, United Kingdom, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: We recently reported prescription opioid use in nearly one-third of systemic lupus erythematosus (SLE) patients in our population-based cohort. Data suggest that opioids may…
Abstract Number: 2554 • 2019 ACR/ARP Annual Meeting
Do All Patients Who Achieve Lupus Low Disease Activity State Have Similar Outcomes?
Konstantinos Tselios¹, Dafna Gladman ², Jiandong Su ³ and Murray Urowitz ¹, ¹University Health Network, University of Toronto, Toronto, Canada, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Lupus Low Disease Activity State (LLDAS) has been associated with favourable outcomes in systemic lupus erythematosus (SLE). However, the complexity of its defining criteria…
Abstract Number: 2555 • 2019 ACR/ARP Annual Meeting
Antimalarial-Induced Cardiomyopathy: Outcome in 10 Patients
Konstantinos Tselios¹, Dafna Gladman ², Shadi Akhtari ³, Paula Harvey ³, Kate Hanneman ⁴ and Murray Urowitz ⁵, ¹University Health Network, University of Toronto, Toronto, Canada, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³Women's College Hospital, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Antimalarial-induced cardiomyopathy (AMIC) is a hypertrophic cardiomyopathy with conduction system disorders, cardiac biomarker abnormalities and a short-term mortality of 45%. Data on the reversibility…
Abstract Number: 2556 • 2019 ACR/ARP Annual Meeting
Histologic Findings from Paired Renal Biopsies and Clinical Outcomes: Results from a Single Site in the Phase III Study of Abatacept in Patients with Proliferative LN
Ana Malvar¹, Valeria Alberton ², Cecilia Recalde ², Sheng Gao ³ and Michael Maldonado ³, ¹Hospital Fernandez; Organización Maedica de Investigación, Buenos Aires, Argentina, ²Hospital Fernandez, Buenos Aires, Argentina, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Current therapeutic management of active Class III or IV proliferative LN relies on the use of maintenance therapy following induction. The optimal method for…
Abstract Number: 2557 • 2019 ACR/ARP Annual Meeting
Proton Pump Inhibitor Induced Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics and Outcomes – Case Control Study
Abdulrahman Alrashid¹, Yih Jia Poh ², David D'Cruz ³, Shirish Sangle ⁴, David McGibbon ⁵, Emma Benton ⁶ and Eleanor Higgins ⁵, ¹King Abdulaziz Medical City - Riyadh, Riyadh, Saudi Arabia, ²Singapore General Hospital, Singapore, Singapore, ³The Louise Coote Lupus Unit, Guy's Hospital, London, England, United Kingdom, ⁴Guy's & St Thomas' Hospitals NHS Foundation Trust, London, England, United Kingdom, ⁵Guy's and St Thomas Foundation Trust, London, United Kingdom, ⁶Guy's and t Thomas Foundation Trust, London, United Kingdom
Background/Purpose: Drug induced subacute cutaneous lupus erythematosus has rarely been described. There is a growing literature reporting the association between proton pump inhibitor (PPI) use…
Abstract Number: 2558 • 2019 ACR/ARP Annual Meeting
Profiling of Gene Expression, Immune Cell Subtypes, and Circulating Protein Biomarkers in Systemic Lupus Erythematosus Patients Treated with the Selective Immunoproteasome Inhibitor, KZR-616
R Andrea Fan¹, Janet Anderl ¹, Brian Tuch ², Darrin Bomba ¹, Niti Goel ³ and Christopher Kirk ¹, ¹Kezar Life Sciences, South San Francisco, CA, ²Kezar Life Sciences, south san francisco, ³Kezar Life Sciences, Duke University School of Medicine, South San Francisco, CA
Background/Purpose: KZR-616 is a selective inhibitor of the immunoproteasome, the form of proteasome found predominantly in immune cells. In nonclinical studies, KZR-616 blocks acute production…
Abstract Number: 2559 • 2019 ACR/ARP Annual Meeting
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of Anifrolumab in Adults with Systemic Lupus Erythematosus
W. Winn Chatham ¹, Richard Furie ², Amit Saxena ³, Philip Brohawn ⁴, Erik Schwetje⁵, Gabriel Abreu ⁶ and Raj Tummala ⁵, ¹University of Alabama Medical Center, Birmingham, AL, ²Zucker School of Medicine at Hofstra/Northwell, New York, NY, ³NYU Langone Orthopedic Center, New York, ⁴AstraZeneca, Gaithersburg, MD, ⁵AstraZeneca, Gaithersburg, MD, USA, Gaithersburg, MD, ⁶AstraZeneca, Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: Anifrolumab is a fully human, IgG1κ monoclonal antibody that binds to the type I IFN receptor and inhibits activity of all type I IFNs.1…
Abstract Number: 2560 • 2019 ACR/ARP Annual Meeting
Factors Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus Patients with End Stage Renal Disease
Maria Salgado Guerrero¹, Alejandra Londono Jimenez ², Chrisanna Dobrowolsky ², Shudan Wang ², Wenzhu B. Mowrey ³ and Anna Broder ², ¹Internal Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²Rheumatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Hydroxychloroquine (HCQ) use in SLE has been associated with a lower risk of end-organ damage, SLE flares, and thrombosis1,2. However the benefits of HCQ…
Abstract Number: 2561 • 2019 ACR/ARP Annual Meeting
Deep Remission During Induction Therapy for Lupus Nephritis Prevents Damage Accrual and Associates with the Baseline Proportions of Peripheral Treg, CD8+ T Cells, and NKT-like Cells
Jun Kikuchi¹, Hironari Hanaoka ¹, Shuntaro Saito ¹, Tatsuhiro Oshige ¹, Kazuoto Hiramoto ¹, Yuko Kaneko ¹, Noriyasu Seki ², Hideto Tsujimoto ² and Tsutomu Takeuchi ¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Mitsubishi Tanabe Pharma Corporation Sohyaku. Innovative Research Division, Toda-shi, Saitama, Japan
Background/Purpose: chievement of renal remission has been the target of the induction therapy in patients with active lupus nephritis (LN). Deep remission (DR) defined as…
Abstract Number: 2562 • 2019 ACR/ARP Annual Meeting
Glucocorticosteroid Usage and Major Organ Damage in Patients with Systemic Lupus Erythematosus – Meta-analyses of Observational Studies Published Between 1979 and 2018
Anselm Mak¹, Mike W.L.- Cheung ¹, Wai Yee Joanna Leong ², Bhushan Dharmadhikari ³, Nien Yee Kow ³, Michelle Petri ⁴, Susan Manzi ⁵, Ann Clarke ⁶, Cynthia Aranow ⁷, Laurent Arnaud ⁸, Anca Askanase ⁹, Sang-Cheol Bae ¹⁰, Sasha Bernatsky ¹¹, Ian Bruce ¹², Jill Buyon ¹³, W. Winn Chatham ¹⁴, Nathalie Costedoat-Chalumeau ¹⁵, MA Dooley ¹⁶, Paul Fortin ¹⁷, Ellen M Ginzler ¹⁸, Dafna Gladman ¹⁹, Caroline Gordon ²⁰, John G Hanly ²¹, Murat Inanc ²², David A Isenberg ²³, Soren Jacobsen ²⁴, Judith James ²⁵, Andreas Jönsen ²⁶, Kenneth C Kalunian ²⁷, Diane Kamen ²⁸, S Sam Lim ²⁹, Eric Morand ³⁰, Christine Peschken ³¹, Bernardo A. Pons-Estel ³², Anisur Rahman ³³, Rosalind Ramsey-Goldman ³⁴, Juanita Romero-Diaz ³⁵, Guillermo Ruiz-Irastorza ³⁶, Jorge Sanchez-Guerrero ³⁷, Kristjan Steinsson ³⁸, Elisabet Svenungsson ³⁹, Murray Urowitz ⁴⁰, Ronald van Vollenhoven ⁴¹, Evelyne Vinet ⁴², Alexandre Voskuyl ⁴³, Daniel J Wallace ⁴⁴ and Graciela Alarcón ⁴⁵, ¹National University of Singapore, Singapore, Singapore, ²Changi General Hospital, Singapore, Singapore, ³National University of Singapore, Singapore, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Allegheny Health Network, Pittsburg, PA, ⁶University of Calgary, Calgary, AB, Canada, ⁷Feinstein Institute for Medical Research, Manhasset, NY, ⁸Service de Rhumatologie, Centre National de Référence des Maladies Autoimmunes Systemiques Rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France, ⁹Columbia University Medical Center, New York, NY, ¹⁰Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹²University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ¹³NYU School of Medicine, New York, ¹⁴University of Alabama Medical Center, Birmingham, AL, ¹⁵Cochin University Hospital, Paris, France, ¹⁶UnC Kidney Centre, Chapel Hill, NC, ¹⁷Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ¹⁸State University of New York Downstate Medical Center, Brooklyn, NY, ¹⁹Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ²⁰University of Birmingham, Birmingham, United Kingdom, ²¹Dalhousie University, Halifax, NS, Canada, ²²Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²³Centre for Rheumatology, London, United Kingdom, ²⁴Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ²⁵Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁶Lund University, Lund, Sweden, ²⁷UC San Diego School of Medicine, LaJolla, CA, ²⁸Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ²⁹Emory University, Atlanta, GA, ³⁰Monash University, Melbourne, Victoria, Australia, ³¹University of Manitoba, Winnipeg, Canada, ³²Centro Regional de Enfermedades Autoinmunes y Reumáticas (CREAR), Grupo Oroño, Rosario, Rosario, Argentina, ³³University College London, London, United Kingdom, ³⁴Northwestern University, Chicago, IL, ³⁵Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ³⁶Autoimmune Diseases Unit, Hospital Universitario Cruces, Barakaldo, Spain, Barakaldo, Spain, ³⁷Toronto Western Hospital, Toronto, ON, Canada, ³⁸Landspitali, University Hospital, Reykjavik, Iceland, ³⁹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ⁴⁰University Health Network, University of Toronto, Toronto, ON, Canada, ⁴¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁴²McGill University Health Centre, Montreal, QC, Canada, ⁴³Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁴⁴Cedars-Sinai Medical Centre, Beverly Hills, CA, ⁴⁵University of Alabama at Birmingham, Birmingham
Background/Purpose: The impact of glucocorticoid (GC) use on major organ damage in SLE patients has not been formally studied by amalgamating the relevant data published…
Abstract Number: 2563 • 2019 ACR/ARP Annual Meeting
PK/PD, Safety and Exploratory Efficacy of Subcutaneous Anifrolumab in SLE: A Phase-II Study in Interferon Type I High Patients with Active Skin Disease
Ian Bruce¹, Alireza Nami ², Erik Schwetje ³, M Edward Pierson ⁴, Yen Lin Chia ⁵, Denison Kuruvilla ⁵, Gabriel Abreu ⁶, Raj Tummala ³ and Catharina Lindholm ⁶, ¹University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ²Joint & Muscle Medical Care, Charlotte, NC, US, Charlotte, NC, ³AstraZeneca, Gaithersburg, MD, USA, Gaithersburg, MD, ⁴AstraZeneca, Gaithersburg, MD, US, Gaithersburg, MD, ⁵AstraZeneca, South San Francisco, CA, US, South San Francisco, CA, ⁶AstraZeneca, Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: Anifrolumab, a fully human anti–IFN Type I receptor mAb, is under investigation for the treatment of SLE at a dose of 300 mg intravenously…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].